Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
(Stockholm 23 June 2022) Inhalation Research Services (IRS), ISAB's contract research organization, has signed a contract worth 581,000 SEK with a returning customer following a previous successful research project in February 2022. The customer is a leading nanotechnology company developing inhalable nanoporous particles for drug delivery.
The development of nanoparticles for drug delivery is a fast-moving and high-potential research area, and the customer a leading company in the field.
The customer will once again be using ISAB's in vivo intratracheal exposure module which delivers voluminous data with exceptionally high precision. Unlike conventional `tower testing' technologies it delivers aerosol directly to the lungs of an individual test rodent, bypassing its nose, whilst carefully monitoring aerosol concentration and individual breathing patterns.
The customer will also be using ISAB's ex vivo Isolated Perfused Lung (IPL) solution, specially tailored for aerosols generated by the PreciseInhale[®] system, which delivers low standard deviation dosing rates and high-resolution data of unprecedented quality and detail.
ISAB CEO Manoush Masarrat: "We're delighted that this returning customer has chosen once again to use IRS for its highly innovative research. This is a testament to the success of our previous project and the excellent results our high-precision technology delivers. We look forward to continuing our cooperation."